Double-stranded RNA (dsRNA) can activate potent anti-tumor immunity, but its clinical translation remains challenging. We sought to identify clinically applicable strategies to induce endogenous dsRNA and enhance anti-tumor immune responses. Here, we integrated genome-wide CRISPR-Cas9 screening data with the Therapeutic Target Database (TTD) and identified Topoisomerase I (TOP1) as a potential inducer of dsRNA. Mechanistically, we found that TOP1 was associated with suppression of endogenous retroviruses (ERVs) in an enzyme activity-dependent manner, and this was accompanied by "viral mimicry" through the induction of dsRNA. Pharmacological inhibition of TOP1 using Irinotecan (CPT-11) triggered dsRNA accumulation across cancer models, including patient-derived organoids (PDOs), activating the RIG-I/MDA5-MAVS pathway and antiviral interferon responses (Type I/III IFNs, ISGs). scRNA-seq revealed that CPT-11 remodeled the tumor microenvironment, promoting infiltration of dendritic cells (DCs), macrophages, and T cells. Combining CPT-11 with PD-1 blockade in "cold" tumors dramatically improved survival. CPT-11 also generated a potent in situ vaccine effect, establishing immunological memory that prevented tumor rechallenge. Moreover, tumor cells pretreated with CPT-11 in vitro were also able to exert a vaccine-like effect, inhibiting the growth of subsequently inoculated tumors. Collectively, our findings support the repurposing of TOP1 inhibitors such as CPT-11 to harness dsRNA-mediated immune activation for more effective cancer therapy.